Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 5/2014

01.09.2014

Clinical utility of antigen carbohydrate 125 in heart failure

verfasst von: Julio Núñez, Gema Miñana, Eduardo Núñez, Francisco J. Chorro, Vicent Bodí, Juan Sanchis

Erschienen in: Heart Failure Reviews | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

In recent years, there has been a proliferation of new biomarkers with potential prognostic implication in heart failure (HF). Nevertheless, most of them do not fulfill the required criteria for being used in daily clinical practice. Tumor marker antigen carbohydrate 125 (CA125), a glycoprotein widely used for ovarian cancer monitoring, is synthesized by epithelial serous cells in response to fluid accumulation and/or cytokine stimuli. This glycoprotein has been emerged as a potential biomarker in HF. Plasma CA125 correlates with clinical, hemodynamic, and echocardiographic parameters related to the severity of the disease. High levels have shown to be present in the majority of acutely decompensated patients, and in this setting, it has shown to be independently related to mortality or subsequent admission for acute HF. In addition, certain characteristics such as wide availability and the close correlation between plasma changes with disease severity and clinical outcomes have increased the interest of researchers about the potential of this glycoprotein for monitoring and guiding therapy in HF. In this article, we have reviewed the available evidence supporting the potential role of CA125 as a biomarker in HF.
Literatur
1.
Richards AM (2009) What we may expect from biomarkers in Heart Failure. Heart Fail Clin 5:463–470PubMedCrossRef
2.
3.
Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952PubMedCrossRef
4.
Richards AM (2010) New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 63:635–639PubMedCrossRef
5.
Palazzuoli A, Masson S, Ronco C, Maisel A (2013) Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. Heart Fail Rev. doi:10.​1007/​s10741-013-9391-x
6.
Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416PubMedCrossRefPubMedCentral
7.
Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47:263–265PubMedCrossRefPubMedCentral
8.
Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL (1986) Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143–6148PubMed
9.
Canney PA, Moore M, Wilkinson PM, James RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 50:765–769PubMedCrossRefPubMedCentral
10.
Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150–154PubMedCrossRef
11.
Kui Wong N, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS (2003) Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 278:28619–28634PubMedCrossRef
12.
Murdoch WJ, Van Kirk EA, Smedts AM (2006) Complement-inhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 236:54–57PubMedCrossRef
13.
Yoshimura M, Ihara Y, Ohnishi A, Ijuhin N, Nishiura T, Kanakura Y, Matsuzawa Y, Taniguchi N (1996) Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res 56:412–418PubMed
14.
Núñez J, Miñana G, González M, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Chorro FJ, Llàcer A, Miguel A (2011) Antigen carbohydrate 125 in heart failure: not just a surrogate for serosal effusions? Int J Cardiol 146:473–474PubMedCrossRef
15.
Núñez J, Miñana G, Núñez E, Sanchis J (2011) Antigen carbohydrate 125 in heart failure: a promising clinical tool. Int J Cardiol 150:369–370PubMedCrossRef
16.
17.
Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172–175PubMedCrossRef
18.
Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7:840–843PubMedCrossRef
19.
Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in vitro and in vivo studies. Hum Reprod 15:1261–1265PubMedCrossRef
20.
Seo T, Ikeda Y, Onaka H, Hayashi T, Kawaguchi K, Kotake C, Toda T, Kobayashi K (1993) Usefulness of serum CA125 measurement for monitoring pericardial effusion. Jpn Circ J 57:489–494PubMedCrossRef
21.
Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8:270–274PubMedCrossRef
22.
Núñez J, Sanchis J, Bodí V, Fonarow GC, Núñez E, Bertomeu-González V, Miñana G, Consuegra L, Bosch MJ, Carratalá A, Chorro FJ, Llàcer A (2010) Improvement in risk stratification with the combination of the tumor marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752–1763PubMedCrossRef
23.
Topatan B, Basaran A (2010) CA-125 and heart failure: déjà vu or “still to be seen”. Int J Cardiol 145:626–629PubMedCrossRef
24.
Huang F, Chen J, Liu Y, Zhang K, Wang J, Huang H (2012) New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 79:381–383PubMedCrossRef
25.
Miñana G, Núñez J, Sanchis J, Bodí V, Núñez E, Llàcer A (2010) CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol 145:547–548PubMedCrossRef
26.
Hamdy NM, Basaran A (2011) Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 17:CR174–CR179PubMedCrossRef
27.
Núñez J, González M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau P, Merlos P, Llàcer A, Miguel A (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548PubMedCrossRef
28.
Colombo PC, Jorde UP (2010) The active role of venous congestion in the pathophysiology of acute decompensated heart failure. Rev Esp Cardiol 63:5–8CrossRef
29.
Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G, European Society of Cardiology; European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12:423–433PubMedCrossRef
30.
Bonfils PK, Damgaard M, Taskiran M, Goetze JP, Norsk P, Gadsbøll N (2010) Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. Eur J Heart Fail 12:995–1001PubMedCrossRef
31.
Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935–2012PubMedCrossRef
32.
Núñez J, Núñez E, Consuegra L, Sanchis J, Bodí V, Martínez-Brotons A, Bertomeu-González V, Robles R, Bosch MJ, Fácila L, Darmofal H, Llàcer A (2007) Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93:716–721PubMedCrossRefPubMedCentral
33.
D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41:1805–1811PubMedCrossRef
34.
Faggiano P, D’Aloia A, Brentana L, Bignotti T, Fiorina C, Vizzardi E, Dei Cas L (2005) Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7:57–61PubMedCrossRef
35.
Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7:199–203PubMedCrossRef
36.
Duman D, Palit F, Simsek E, Bilgehan K (2008) Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 10:556–559PubMedCrossRef
37.
Nägele H, Bahlo M, Klapdor R, Rödiger W (1999) Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Anticancer Res 19:2531–2534PubMed
38.
Hung CL, Hung TC, Liu CC, Wu YJ, Kuo JY, Hou CJ, Yeh HI (2012) Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol 110:993–1000PubMedCrossRef
39.
Yilmaz MB, Zorlu A, Tandogan I (2011) Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol 149:80–82PubMedCrossRef
40.
Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W (1999) CA 125 and its relation to cardiac function. Am Heart J 137:1044–1049PubMedCrossRef
41.
Ordu S, Ozhan H, Alemdar R, Aydin M, Caglar O, Yuksel H, Kandis H (2012) Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication. Tex Heart Inst J 39:30–35PubMedPubMedCentral
42.
Mansour IN, Napan S, Tarek Alahdab M, Stamos TD (2010) Carbohydrate antigen 125 predicts long-term mortality in African American patients with acute decompensated heart failure. Congest Heart Fail 16:15–20PubMedCrossRef
43.
Vizzardi E, D’Aloia A, Pezzali N, Bugatti S, Curnis A, Dei Cas L (2012) Long-term prognostic value of CA 125 serum levels in mild to moderate heart failure patients. J Card Fail 18:68–73PubMedCrossRef
44.
Monteiro S, Franco F, Costa S, Monteiro P, Vieira H, Coelho L, Oliveira L, Providência LA (2010) Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol 140:115–118PubMedCrossRef
45.
Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406–412PubMedCrossRef
46.
Varol E, Yücel H, Arslan A, Ozaydın M, Erdoğan D, Doğan A (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40:309–315PubMedCrossRef
47.
Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A, Dede O (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22:30–33PubMedCrossRef
48.
Karaca O, Guler GB, Guler E, Gunes HM, Alizade E, Agus HZ, Gol G, Kahveci G, Esen O, Esen AM, Turkmen M (2012) Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 18:144–150PubMedCrossRef
49.
Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC, Miñana G, Palau P, Bertomeu-González V, Carratalá A, Mainar L, Chorro FJ, Llàcer A (2012) CA125 and BNP serial measurements for risk stratification following an episode of acute heart failure. Int J Cardiol 159:21–28PubMedCrossRef
50.
Miñana Escrivá G, Núñez J, Sanchis J, Bodi V, Núñez E, Chorro FJ, Llàcer A (2012) Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission. Med Clin (Barc) 139:479–486CrossRef
51.
Husser O, Nunez J, Nunez E, Holzamer A, Camboni D, Luchner A, Sanchis J, Bodi V, Riegger G, Schmid C, Hilker M, Hengstenberg C (2013) Tumor marker carbohydrate antigen 125 predicts adverse outcome after transcatheter aortic valve implantation. JACC Cardiovasc Interv 6:487–496PubMedCrossRef
52.
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003CrossRef
53.
Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367–377PubMedCrossRef
54.
Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695–1707PubMed
55.
O’Donoghue M, Braunwald E (2010) Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7:13–20PubMedCrossRef
56.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261PubMedCrossRef
57.
Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G (2008) Effect of rosuvastatin in patients with chronic heart failure (the gissi-hf trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231–1239PubMedCrossRef
58.
McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef
59.
Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, Komuro I, PEARL Study Investigators (2013) Effects of pitavastatin on Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 77:917–925PubMedCrossRef
60.
Núñez J, Sanchis J, Núñez E, Fonarow GC, Bodí V, Bertomeu-González V, Miñana G, Palau P, Fácila L, Chorro FJ, Bertomeu-Martínez V, Llàcer A (2011) Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure. Rev Esp Cardiol 64:1100–1108CrossRef
61.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedCrossRef
62.
Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS (2008) Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 13:211–225PubMedCrossRef
63.
Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. Int J Cardiol 112:234–242PubMedCrossRef
64.
McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009) Effects of statin therapy according to plasma high-sensitivity c-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (corona): a retrospective analysis. Circulation 120:2188–2196PubMedCrossRef
65.
Felker GM, O’Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2:56–62PubMedCrossRefPubMedCentral
66.
Eshaghian S, Horwich TB, Fonarow GC (2009) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764CrossRef
67.
Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439PubMedCrossRefPubMedCentral
68.
Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC, Bertomeu-González V, Palau P, Merlos P, Ventura S, Chorro FJ, Llàcer P, Sanchis J (2012) Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail 14:974–984PubMedCrossRefPubMedCentral
69.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedCrossRefPubMedCentral
70.
Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ (2011) Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 57:2233–2241PubMedCrossRef
71.
van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58:127–138PubMedCrossRef
72.
73.
74.
Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23–35PubMedCrossRef
75.
Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Cardiac Fail 15:256–266CrossRef
76.
Sherwi N, Merali S, Wong K (2012) Personalizing biomarker strategies in heart failure with galectin-3. Future Cardiol 8:885–894PubMedCrossRef
77.
Bhardwaj A, Januzzi JL Jr (2010) ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 10:459–464PubMedCrossRef
Metadaten
Titel
Clinical utility of antigen carbohydrate 125 in heart failure
verfasst von
Julio Núñez
Gema Miñana
Eduardo Núñez
Francisco J. Chorro
Vicent Bodí
Juan Sanchis
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 5/2014
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-013-9402-y

Weitere Artikel der Ausgabe 5/2014

Heart Failure Reviews 5/2014 Zur Ausgabe

OriginalPaper

Critical appraisal of the obesity paradox in cardiovascular disease: How to manage patients with overweight in heart failure?

OriginalPaper

Novel approaches to the post-myocardial infarction/heart failure neural remodeling

OriginalPaper

Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target

OriginalPaper

Predicted values of exercise capacity in heart failure: where we are, where to go

OriginalPaper

Aerobic exercise effect on prognostic markers for systolic heart failure patients: a systematic review and meta-analysis

OriginalPaper

Takotsubo cardiomyopathy

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

13.05.2024 Chronische Herzinsuffizienz Nachrichten

Die Anlage eines interatrialen Shunts zur Reduktion des linksatrialen Drucks ist ein neuer Therapieansatz bei Herzinsuffizienz. Viele Patienten sprechen darauf an, andere jedoch nicht. 

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise